Even before its gene-editing therapy reached (and failed in) a clinical trial, the company executed a $274 million IPO during the Covid-19 biotech boom.
Even before its gene-editing therapy reached (and failed in) a clinical trial, the company executed a $274 million IPO during the Covid-19 biotech boom.
About Our Site:
The primary purpose of the site is to provide Real Estate & Mortgage information as it relates to today’s business environment. It can also be used to answer related question you might have about buying, selling, or financing real estate.